Business
Outset Medical Presenting Research on Human Factors Testing, Home Dialysis Patient Experience and More During ASN Kidney Week 2022
Findings include home dialysis patients treating with the Tablo® Hemodialysis System have lower attrition rates compared to other modalities SAN JOSE,
About this update from Outset Medical, Inc.
[{"type":"text","content":"\nFindings include home dialysis patients treating with the Tablo® Hemodialysis System have lower attrition rates compared to other modalities\n\n SAN JOSE, Calif.--(BUSINESS WIRE)--\nOutset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis with its Tablo® Hemodialysis System, announces the release of eight new groundbreaking abstracts on home dialysis innovation and other important kidney care research.\n\nThe research will be presented at the American Society of Nephrology’s (ASN) Kidney Week 2022 in Orlando, FL, which runs from November 3-6. More than 10,000 kidney professionals from around the world convene at this event to learn the latest scientific and medical advances and discuss kidney care innovations with leading experts in the field.\n\n“The research shows that Tablo is easy to use for patients and healthcare professionals with 100 percent of both groups reporting they can use it safely and effectively,” said Michael Aragon, MD, Chief Medical Officer for Outset Medical. “Our latest research looks at the human factor and how Outset’s kidney innovation can help patients from all backgrounds live their best lives while also considering how to help providers save costs and improve efficiencies.”\n\nKey research findings highlight patient, healthcare professional and supply chain data points.\n\nAbstracts focused on home include:\n\n\nHuman Factors Validation of the Tablo Hemodialysis System in Home Patients – Results from the largest human factors study ever performed on a hemodialysis device, based on the number of tested tasks, demonstrated that patients and care partners can easily and quickly learn to use Tablo. Among patients and their care partners in the study, the observed use error rate was just 0.9% on more than 5,400 tasks tested.\n\n\nSimulating Strategies to Launch a Home Therapies Program in a Conventional Hemodialysis Facility – Home dialysis retention of both incident and prevalent patients, as seen with the Tablo system, can accelerate home growth and revenue.\n\n\nThe Tablo Hemodialysis System at Home: Comparing Real World to the IDE Trial – Observed real-world evidence is similar to the results of the home IDE study: with high treatment adherence, 100% patient retention and achievement of adequacy goals using more flexible dialysis schedule...